References
- Ferreira CR, Altassan R, Marques-Da-Silva D, Francisco R, Jaeken J, Morava E. Recognizable phenotypes in CDG. J Inherit Metab Dis. 2018;41(3):541–53. doi: 10.1007/s10545-018-0156-5
- Francisco R, Marques-da-Silva D, Brasil S, Pascoal C, Dos Reis Ferreira V, Morava E, et al. The challenge of CDG diagnosis. Mol Genet Metab. 2019;126(1):1–5. doi: 10.1016/j.ymg-me.2018.11.003
- Jaeken J, Péanne R. What is new in CDG? J Inherit Metab Dis. 2017;40(4):569–86. doi: 10.1007/s10545-017-0050-6. Erratum in: J Inherit Metab Dis. 2017;40(4):621–5. doi: 10.1007/s10545-017-0068-9
- Péanne R, de Lonlay P, Foulquier F, Kornak U, Lefeber DJ, Morava E, et al. Congenital disorders of glycosylation (CDG): Quo vadis? Eur J Med Genet. 2018;61(11):643–63. doi: 10.1016/j.ejmg.2017.10.012
- Grünewald S. The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta. 2009;1792(9):827– 34. doi: 10.1016/j.bbadis.2009.01.003
- Cabezas OR, Flanagan SE, Stanescu H, García-Martínez E, Caswell R, Lango-Allen H, et al. Polycystic kidney disease with hyperinsulinemic hypoglycemia caused by a promoter mutation in phosphomannomutase 2. J Am Soc Nephrol. 2017;28(8):2529– 39. doi: 10.1681/ASN.2016121312
- Verheijen J, Tahata S, Kozicz T, Witters P, Morava E. Therapeutic approaches in congenital disorders of glycosylation (CDG) involving N-linked glycosylation: an update. Genet Med. 2020;22(2):268–79. doi: 10.1038/s41436-019-0647-2
- Martínez-Monseny AF, Bolasell M, Callejón-Póo L, Cuadras D, Freniche V, Itzep DC, et al. AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG). Ann Neurol. 2019;85(5):740–51. doi: 10.1002/ana.25457
- Jaeken J, Lefeber D, Matthijs G. Clinical utility gene card for: Phosphomannose isomerase deficiency. Eur J Hum Genet. 2014;22(9):1153. doi: 10.1038/ejhg.2014.29
- Diaz J, Kane TD, Leon E. Evidence of GMPPA founder mutation in indigenous Guatemalan population associated with alacrima, achalasia, and mental retardation syndrome. Am J Med Genet A. 2020;182(3):425–30. doi: 10.1002/ajmg.a.61476
- Astrea G, Romano A, Angelini C, Antozzi CG, Barresi R, Battini R, et al. Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study. Orphanet J Rare Dis. 2018;13(1):170. doi: 10.1186/s13023-018-0863-x
- Koch J, Mayr JA, Alhaddad B, Rauscher C, Bierau J, Kovacs-Nagy R, et al. CAD mutations and uridine-responsive epileptic encephalopathy. Brain. 2017;140(2):279–86. doi: 10.1093/brain/aww300
- Radenkovic S, Bird MJ, Emmerzaal TL, Wong SY, Felgueira C, Stiers KM, et al. The metabolic map into the pathomechanism and treatment of PGM1-CDG. Am J Hum Genet. 2019;104(5):835– 46. doi: 10.1016/j.ajhg.2019.03.003
- Jaeken J, Lefeber DJ, Matthijs G. Clinical utility gene card for: PGM3 defective congenital disorder of glycosylation. Eur J Hum Genet. 2019;27(11):1757–60. doi: 10.1038/s41431-019-0453-y
- Schröder KC, Duman D, Tekin M, Schanze D, Sukalo M, Meester J, et al. Adams-Oliver syndrome caused by mutations of the EOGT gene. Am J Med Genet A. 2019;179(11):2246–51. doi: 10.1002/ajmg.a.61313
- Pravata VM, Muha V, Gundogdu M, Ferenbach AT, Kakade PS, Vandadi V, et al. Catalytic deficiency of O-GlcNAc transferase leads to X-linked intellectual disability. Proc Natl Acad Sci USA. 2019;116(30):14961–70. doi: 10.1073/pnas.1900065116
- Lam BL, Züchner SL, Dallman J, Wen R, Alfonso EC, Vance JM, et al. Mutation K42E in dehydrodolichol diphosphate synthase (DHDDS) causes recessive retinitis pigmentosa. Adv Exp Med Biol. 2014;801:165–70. doi: 10.1007/978-1-4614-3209-8_21
- Hamdan FF, Myers CT, Cossette P, Lemay P, Spiegelman D, Laporte AD, et al. High rate of recurrent De Novo mutations in developmental and epileptic encephalopathies. Am J Hum Genet. 2017;101(5):664–85. doi: 10.1016/j.ajhg.2017.09.008
- Ng BG, Shiryaev SA, Rymen D, Eklund EA, Raymond K, Kircher M, et al. ALG1-CDG: clinical and molecular characterization of 39 unreported patients. Hum Mutat. 2016;37(7):653–60. doi: 10.1002/humu.22983
- Morava E, Tiemes V, Thiel C, Seta N, de Lonlay P, de Klerk H, et al. ALG6-CDG: a recognizable phenotype with epilepsy, proximal muscle weakness, ataxia and behavioral and limb anomalies. J Inherit Metab Dis. 2016;39(5):713–23. doi: 10.1007/s10545-016-9945-x. Erratum in: J Inherit Metab Dis. 2016 Sep;39(5):759. doi: 10.1007/s10545-016-9967-4
- Davis K, Webster D, Smith C, Jackson S, Sinasac D, Seargeant L, et al. ALG9-CDG: new clinical case and review of the literature. Mol Genet Metab Rep. 2017;13:55–63. doi: 10.1016/j. ymgmr.2017.08.004
- Besse W, Chang AR, Luo JZ, Triffo WJ, Moore BS, Gulati A, et al. ALG9 mutation carriers develop kidney and liver cysts. J Am Soc Nephrol. 2019;30(11):2091–102. doi: 10.1681/ASN.2019030298
- Ng BG, Underhill HR, Palm L, Bengtson P, Rozet JM, Gerber S, et al. DPAGT1 deficiency with encephalopathy (DPAGT1-CDG): clinical and genetic description of 11 new patients. JIMD Rep. 2019;44:85–92. doi: 10.1007/8904_2018_128
- Pode-Shakked B, Heimer G, Vilboux T, Marek-Yagel D, Ben-Zeev B, Davids M, et al. Cerebral and portal vein thrombosis, macrocephaly and atypical absence seizures in Glycosylphosphatidyl inositol deficiency due to a PIGM promoter mutation. Mol Genet Metab. 2019;128(1–2):151–61. doi: 10.1016/j.ymg-me.2019.08.003
- Rush ET, Baker CV, Rizzo WB. Dolichol kinase deficiency (DOLK-CDG): two new cases and expansion of phenotype. Am J Med Genet A. 2017;173(9):2428–34. doi: 10.1002/ajmg.a.38287
- Li M, Cheng R, Liang J, Yan H, Zhang H, Yang L, et al. Mutations in POFUT1, encoding protein O-fucosyltransferase 1, cause generalized Dowling-Degos disease. Am J Hum Genet. 2013;92(6):895–903. doi: 10.1016/j.ajhg.2013.04.022. Epub 2013 May 16. Erratum in: Am J Hum Genet. 2013;92(6):1014.
- Takeuchi H, Wong D, Schneider M, Freeze HH, Takeuchi M, Berardinelli SJ, et al. Variant in human POFUT1 reduces enzymatic activity and likely causes a recessive microcephaly, global developmental delay with cardiac and vascular features. Glycobiology. 2018;28(5):276–283. doi: 10.1093/glycob/cwy014
- Bianchi P, Schwarz K, Högel J, Fermo E, Vercellati C, Grosse R, et al. Analysis of a cohort of 101 CDAII patients: description of 24 new molecular variants and genotype-phenotype correlations. Br J Haematol. 2016;175(4):696–704. doi: 10.1111/bjh.14271
- Farhan SM, Wang J, Robinson JF, Prasad AN, Rupar CA, Siu VM, et al. Old gene, new phenotype: mutations in heparan sulfate synthesis enzyme, EXT2 leads to seizure and developmental disorder, no exostoses. J Med Genet. 2015;52(10):666–75. doi: 10.1136/jmedgenet-2015-103279
- Jaeken J, Lefeber DJ, Matthijs G. Clinical utility gene card For: GALNT3 defective congenital disorder of glycosylation. Eur J Hum Genet. 2018;26(8):1230–3. doi: 10.1038/s41431-017-0002-5
- Ng BG, Sosicka P, Agadi S, Almannai M, Bacino CA, Barone R, et al. SLC35A2-CDG: functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported individuals. Hum Mutat. 2019;40(7):908–925. doi: 10.1002/humu.23731
- Dörre K, Olczak M, Wada Y, Sosicka P, Grüneberg M, Reunert J, et al. A new case of UDP-galactose transporter deficiency (SLC35A2-CDG): molecular basis, clinical phenotype, and therapeutic approach. J Inherit Metab Dis. 2015;38(5):931–40. doi: 10.1007/s10545-015-9828-6
- Winawer MR, Griffin NG, Samanamud J, Baugh EH, Rathakrishnan D, Ramalingam S, et al. Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol. 2018;83(6):1133–46. doi: 10.1002/ana.25243
- Ferreira CR, Xia ZJ, Clément A, Parry DA, Davids M, Taylan F, et al. A recurrent De Novo heterozygous COG4 substitution leads to Saul-Wilson syndrome, disrupted vesicular trafficking, and altered proteoglycan glycosylation. Am J Hum Genet. 2018;103(4):553– 67. doi: 10.1016/j.ajhg.2018.09.003
- Bui C, Huber C, Tuysuz B, Alanay Y, Bole-Feysot C, Leroy JG, et al. XYLT1 mutations in Desbuquois dysplasia type 2. Am J Hum Genet. 2014;94(3):405–14. doi: 10.1016/j.ajhg.2014.01.020
- LaCroix AJ, Stabley D, Sahraoui R, Adam MP, Mehaffey M, Kernan K, et al. GGC Repeat expansion and exon 1 methylation of XYLT1 is a common pathogenic variant in Baratela-Scott syndrome. Am J Hum Genet. 2019;104(1):35–44. doi: 10.1016/j. ajhg.2018.11.005
- Balasubramanian M, Johnson DS; DDD Study. MAN1B-CDG: Novel variants with a distinct phenotype and review of literature. Eur J Med Genet. 2019;62(2):109–114. doi: 10.1016/j.ejmg.2018.06.011
- Park JH, Hogrebe M, Fobker M, Brackmann R, Fiedler B, Reunert J, et al. SLC39A8 deficiency: biochemical correction and major clinical improvement by manganese therapy. Genet Med. 2018;20(2):259–68. doi: 10.1038/gim.2017.106
- Zaum AK, Kolokotronis K, Kress W, Goebel HH, Rost S, Seeger J. A new case expanding the mutation and phenotype spectrum of TMEM5-related alpha-dystroglycanopathy. Neuromuscul Disord. 2018;28(8):671–4. doi: 10.1016/j.nmd.2018.06.006